Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume

Frederick L. Locke, Olalekan O. Oluwole, John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Gilles Salles, Steven P. Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten

Blood (2024) 143 (24): 2464–2473.

https://doi.org/10.1182/blood.2023021620

Published: 2024

Includes: Supplemental data

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

The quest for a cure in follicular lymphoma

Sanne H. Tonino, Marie José Kersten

Blood (2024) 143 (6): 475–476.

https://doi.org/10.1182/blood.2023022796

Published: 2024

Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang

Blood (2023) 142 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2023-174681

Published: 2023

Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

Marie José Kersten, Kirsten Saevels, Yves Beguin, Joost S.P Vermaat, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden, Maria T. Kuipers, Sébastien Anguille

Blood (2023) 142 (Supplement 1): 2113.

https://doi.org/10.1182/blood-2023-172736

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Ramon Garcia-Sanz, Roger Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2023-174294

Published: 2023

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Blood (2022) 140 (Supplement 1): 3534–3536.

https://doi.org/10.1182/blood-2022-159036

Published: 2022

Journal Articles

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3523–3524.

https://doi.org/10.1182/blood-2022-165494

Published: 2022

Journal Articles

A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC -Rearranged DLBCL Patients

A. Vera de Jonge, Erik D. van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G.G.M. Rutten, Rogier Mous, Joost S.P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry R. Koene, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 2059–2060.

https://doi.org/10.1182/blood-2022-163204

Published: 2022

Journal Articles

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Armin Ghobadi, Javier Munoz, Jason Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 1595–1597.

https://doi.org/10.1182/blood-2022-158303

Published: 2022

Journal Articles

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Erik Van Dijk, Jurriaan Janssen, Matias Mendeville, G. Tjitske Los-De Vries, Margaretha GM Roemer, Phylicia Stathi, Julia Richter, Yong Soo Kim, Wolfram Klapper, Ulrich Dührsen, Andreas Hüttmann, P. J Lugtenburg, Josée M. Zijlstra, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau, Bauke Ylstra

Blood (2022) 140 (Supplement 1): 9261–9263.

https://doi.org/10.1182/blood-2022-160052

Published: 2022

Journal Articles

Therapies and Outcomes for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Contemporary, Nationwide, Population-Based Study in the Netherlands

Elise R.A. Pennings, Müjde Durmaz, Otto Visser, Eduardus F.M. Posthuma, Djamila E. Issa, Martine E.D. Chamuleau, Pieternella Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed

Blood (2022) 140 (Supplement 1): 9564–9566.

https://doi.org/10.1182/blood-2022-159376

Published: 2022

Journal Articles

Fatigue, Neuropathy, Psychological Distress and Their Association with Health-Related Quality of Life in Survivors of Diffuse Large B-Cell Lymphoma: A Prospective Cohort Study and Comparison with a Normative Population

Suzanne Neppelenbroek, Afke Ekels, Marie Jose Kersten, Flora Van Leeuwen, Djamila E. Issa, Noortje Thielen, Lonneke van de Poll-Franse, Simone Oerlemans

Blood (2022) 140 (Supplement 1): 1929–1930.

https://doi.org/10.1182/blood-2022-155962

Published: 2022

Journal Articles

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Julia Driessen, Wouter J. Plattel, Lydia Visser, Anke Van Den Berg, Josée M. Zijlstra, Sanne Tonino, Gerben JC Zwezerijnen, Ronald Boellaard, Marie José Kersten, Arjan Diepstra

Blood (2022) 140 (Supplement 1): 9213–9215.

https://doi.org/10.1182/blood-2022-166120

Published: 2022

Journal Articles

Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

Blood (2022) 140 (Supplement 1): 164–165.

https://doi.org/10.1182/blood-2022-156103

Published: 2022

NARROW

Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

The quest for a cure in follicular lymphoma

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC -Rearranged DLBCL Patients

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Therapies and Outcomes for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Contemporary, Nationwide, Population-Based Study in the Netherlands

Fatigue, Neuropathy, Psychological Distress and Their Association with Health-Related Quality of Life in Survivors of Diffuse Large B-Cell Lymphoma: A Prospective Cohort Study and Comparison with a Normative Population

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only